Mirion Technologies delivered an in-line third quarter. The more important story was a split between demand and margins. Adjusted earnings of $0.12 per share matched consensus. Revenue of $277.8 million was essentially on top of the $277.91 million estimate and up 24.5% year over year. Earnings grew 9.1% on Earnings Whispers' normalized basis. Beneath that tidy headline, the quarter moved in two directions. Orders and the revenue outlook accelerated sharply. At the same time, management withdrew the 2028 30% adjusted EBITDA margin target it had reaffirmed on the first- and second-quarter calls. That is the central tension: the top line is getting stronger while the profitability story is being reset lower.

The quality of the quarter is better on the top line than the headline growth rate suggests, but weaker on margins. Much of the 24.5% revenue gain came from acquisitions, including Paragon and Certrec. Organic growth was 6.5%, a clear inflection from 3% in the first quarter and 1% in the second, though slightly below the high-single-digit pace management guided to in July. Adjusted EBITDA rose 23.7% to $64.8 million, roughly matching revenue growth. However, the adjusted EBITDA margin slipped to 23.3% from 23.5%, missing July's call for expansion. Nuclear & safety margin fell to 25.7% from 28.1%, including one-time adjustments on legacy Paragon projects. GAAP results improved more visibly: operating margin rose to 6.2% from 3.3%, and net income climbed to $7.8 million from $3.1 million. One comparability point matters for the EPS line. The company's own presentation shows adjusted EPS flat at $0.12, but the current period now absorbs $7.1 million of stock-based compensation that was excluded a year ago. On a like-for-like basis, the underlying improvement is somewhat better than the flat company-reported figure implies.

The demand data is where the call earned its credibility. Organic orders jumped 62% to $340 million, accelerating from 10% growth in the second quarter and 19% in the first. Nuclear power orders rose 105%, or 134% excluding a China de-booking. Backlog reached $1.25 billion, up from $816 million a year ago, and roughly $735 million is slated to convert in the fourth quarter and fiscal 2027. Nuclear power organic revenue grew 14% after a flat first half. Medical rebounded to 6.7% organic growth from a 1% decline in the second quarter. Management continues to emphasize that about 80% of nuclear power revenue comes from the existing reactor fleet. That makes the growth less dependent on speculative new builds than the small modular reactor narrative might suggest. Supporting the fleet thesis, the NRC has proposed allowing license renewals of up to 40 years, and roughly 1.5 GW of U.S. uprates have recently been announced.

Guidance reflected the same split. Full-year organic growth was raised to 7%-8% from 5%-7%, and total growth to 24%-25%. Adjusted free cash flow guidance rose to $170 million-$185 million, with conversion lifted to 60%-63%. Against that, the top end of adjusted EBITDA guidance was cut to $292 million, the margin range fell to 24.7%-25.2% from 25%-26%, and the adjusted EPS range narrowed to $0.50-$0.54. Management attributed the reset to several factors:

• AI and cybersecurity spending running above budget;
• a slower Paragon margin ramp;
• a two-year flat spot in medical margins;
• price/cost that is neutral in dollars but dilutive to margin rate.

Mirion now frames its ambition as one to two points of annual margin expansion, described as preliminary, with more detail promised at a 2027 investor day. Bears have legitimate ammunition here. The fourth-quarter guide calls for mid-to-high-teens organic growth, an aggressive back-end load after a quarter that slightly missed its own organic guide. The company also faces a tough fourth-quarter orders comparison against last year's record quarter. More than $80 million of EDF orders remain outside backlog pending EU funding. Net leverage rose to 3.1x after buybacks, even as a new $250 million repurchase program was announced, so the year-end target of roughly 2.6x now carries real weight.

Investor sentiment improved meaningfully heading into the report, moving from -0.48 to -0.18. It remains negative but is considerably less so. The share price tells a less forgiving story. At $15.41, the stock is down 11.8% since the open following the July report and sits 16.5% below its 200-day moving average of $18.46. The AVWAP trend reading remains negative while the price trend is neutral. In other words, the market had already been marking the stock down before this margin reset became explicit.

The bottom line is that Mirion's quarter strengthened the demand case and weakened the margin case at the same time. Record-pace nuclear orders, a $1.25 billion backlog and better cash conversion make the growth story more credible than it was in July. The abandoned 30% margin target, however, removes a key pillar of the earnings-leverage thesis. With shares well below their 200-day average, investors are likely to look for delivery of the steep fourth-quarter organic ramp and visible margin progress before giving the order surge full credit.